Logo Prima Biomed

Welcome to the Newsroom

09 November 2017

New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting



SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead product candidate, in combination with pembrolizumab (KEYTRUDA) in unresectable or metastatic melanoma patients.